Immunic’s (IMUX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Immunic (NASDAQ:IMUX) in a report released on Friday morning,Benzinga reports. They currently have a $10.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the company. D. Boral Capital restated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Thursday. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $12.67.

Immunic Trading Up 6.6 %

Shares of NASDAQ IMUX opened at $1.26 on Friday. The stock has a market cap of $113.32 million, a P/E ratio of -1.02 and a beta of 1.87. The stock has a 50 day moving average of $1.02 and a two-hundred day moving average of $1.26. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11.

Hedge Funds Weigh In On Immunic

Hedge funds and other institutional investors have recently bought and sold shares of the company. Focus Partners Wealth grew its holdings in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after purchasing an additional 23,610 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Immunic by 480.6% in the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after purchasing an additional 177,542 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its stake in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. 51.82% of the stock is owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.